These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
766 related articles for article (PubMed ID: 11761458)
1. In vitro studies on the mechanisms of oxaliplatin resistance. Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458 [TBL] [Abstract][Full Text] [Related]
2. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W; Chaney SG Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361 [TBL] [Abstract][Full Text] [Related]
3. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Hector S; Nava ME; Clark K; Murphy M; Pendyala L Cancer Lett; 2007 Jan; 245(1-2):195-204. PubMed ID: 16516375 [TBL] [Abstract][Full Text] [Related]
4. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093 [TBL] [Abstract][Full Text] [Related]
5. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models. Deqnah N; Yu JQ; Beale P; Fisher K; Huq F Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298 [TBL] [Abstract][Full Text] [Related]
6. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681 [TBL] [Abstract][Full Text] [Related]
7. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants. Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003 [TBL] [Abstract][Full Text] [Related]
8. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. O'Neill CF; Koberle B; Masters JR; Kelland LR Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725 [TBL] [Abstract][Full Text] [Related]
9. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs. Corte-Rodríguez M; Espina M; Sierra LM; Blanco E; Ames T; Montes-Bayón M; Sanz-Medel A Biochem Pharmacol; 2015 Nov; 98(1):69-77. PubMed ID: 26352094 [TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380 [TBL] [Abstract][Full Text] [Related]
11. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617 [TBL] [Abstract][Full Text] [Related]
12. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489 [TBL] [Abstract][Full Text] [Related]
13. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP. Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and antitumour activity of a new trinuclear platinum compound [{cis-PtCl(NH3)2μ {trans-Pt(3-hydroxypyridine)2H2N(CH2)5NH2)2}] Cl4 in human ovarian cancer cells. Hamad SA; Beale P; Yu JQ; Huq F Anticancer Res; 2014 Apr; 34(4):1923-9. PubMed ID: 24692727 [TBL] [Abstract][Full Text] [Related]
15. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells. Ekblad L; Kjellström J; Johnsson A Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208 [TBL] [Abstract][Full Text] [Related]
16. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117 [TBL] [Abstract][Full Text] [Related]
17. Analysis of cytotoxicities of platinum compounds. Goodisman J; Hagrman D; Tacka KA; Souid AK Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101 [TBL] [Abstract][Full Text] [Related]
18. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Li Q; Yu JJ; Mu C; Yunmbam MK; Slavsky D; Cross CL; Bostick-Bruton F; Reed E Anticancer Res; 2000; 20(2A):645-52. PubMed ID: 10810335 [TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Luo FR; Wyrick SD; Chaney SG Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941 [TBL] [Abstract][Full Text] [Related]
20. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin. Parker RJ; Vionnet JA; Bostick-Bruton F; Reed E Cancer Res; 1993 Jan; 53(2):242-7. PubMed ID: 8417816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]